Published on European Cystic Fibrosis Society (ECFS) (https://www.ecfs.eu)

Home > A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutati

A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutati

Resource Type

CF Research News

Authors

Jane C Davies, Isabelle Sermet-Gaudelus, Lutz Naehrlich, R Scott Harris, Daniel Campbell, Neil Ahluwalia, Christopher Short, Eric Haseltine, Paul Panorchan, Clare Saunders, Caroline A Owen, Claire E Wainwright, VX16-661-115 Investigator Group

References

J Cyst Fibros . 2020 Sep 21;S1569-1993(20)30811-0. doi: 10.1016/j.jcf.2020.07.023.

Document

PDF icon CF Research News Article [1]

Link

Scientific Abstract [2]

Keywords

Clinical trial [3]
F508del-CFTR mutation [4]
Ivacaftor [5]
Lung clearance index [6]
Residual function CFTR mutation [7]
Tezacaftor [8]

Date

Monday, September 21, 2020

Featured resource article

Yes

Resource - Guideline Type

Other Guidelines [9]
Source URL:https://www.ecfs.eu/resource-article/cf-research-news/phase-3-double-blind-parallel-group-study-evaluate-efficacy-and

Links
[1] https://www.ecfs.eu/sites/default/files/cf-research-article-files/JCF-D-20-00261R1_FINAL_Davies_191120.pdf [2] https://pubmed.ncbi.nlm.nih.gov/32967799/ [3] https://www.ecfs.eu/research-article-keywords/clinical-trial [4] https://www.ecfs.eu/research-article-keywords/f508del-cftr-mutation [5] https://www.ecfs.eu/research-article-keywords/ivacaftor [6] https://www.ecfs.eu/research-article-keywords/lung-clearance-index [7] https://www.ecfs.eu/research-article-keywords/residual-function-cftr-mutation [8] https://www.ecfs.eu/research-article-keywords/tezacaftor [9] https://www.ecfs.eu/resource-guideline-type/other-guidelines